



July 18, 2012

Subject: Model Performance Evaluation Program for *Mycobacterium tuberculosis* and Nontuberculous Mycobacteria Drug Susceptibility Testing (MTB NTM DST) Preliminary Report for May 2012

Dear Participant:

Attached you will find the preliminary susceptibility testing results for the cultures of *M. tuberculosis* sent to your laboratory in May 2012. (You may also access the report at <http://wwwn.cdc.gov/mpep/mtbds.aspx>) These preliminary results were determined by the candidate reference laboratories and may not represent the consensus of all participants. Although CDC recommends the broth-based methods for routine *M. tuberculosis* drug susceptibility testing, this preliminary report provides the results obtained by using the reference agar proportion method, except in the case of pyrazinamide, where BACTEC MGIT 960 is the reference method. Participants should use the equivalent critical concentrations for testing methods, as defined in CLSI M24-A2 standards, to determine their results.

This preliminary report provides you with the initial information about the cultures sent to your laboratory. Subsequently, a detailed aggregate report of susceptibility testing results and methods reported by all participants for this panel of five (5) *M. tuberculosis* complex isolates will be emailed.

For additional information or to comment on this report, you may call Dr. Pawan Angra at 1-888-465-6062 or 404 718-4607 or email mtbntmdst@cdc.gov or Pangra@cdc.gov. You may also contact Dr. Beverly Metchock at 404 639-1285 or email BMetchock@cdc.gov.

We appreciate your continued interest and participation in the CDC Model Performance Evaluation Program for *Mycobacterium tuberculosis* and Nontuberculous Mycobacteria Drug Susceptibility Testing (MTB NTM DST).

Sincerely yours,

Pawan Angra, MS, PhD
Project Coordinator
Model Performance Evaluation Program
NCEZID/DPEI/LSDB
Centers for Disease Control and Prevention
Ph : 404-718-4607
email : Pangra@cdc.gov

Preliminary Report

Susceptibility Testing Results:
***M. tuberculosis* Isolates**
Panel Shipment May 07, 2012

Isolate	Susceptibility Testing Results
2012A	Resistant to Rifampin, Streptomycin, and Kanamycin
2012B	Resistant to Isoniazid, Ethambutol, Kanamycin, Capreomycin and Amikacin
2012C	Resistant to Kanamycin, Capreomycin, and Amikacin
2012D	Resistant to Ofloxacin
2012E	Resistant to Streptomycin